Medicenna Therapeutics Corp

TSX:MDNACanadaView on Grey Market

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Contact Information

Headquarters

2 Bloor St W 7th FloorTORONTO, ON, Canada M4W 3E2

Phone

416-648-5555

Fax

416-648-5555

Executives

Chairman of the Board, President, Chief Executive Officer

Fahar Merchant

Chief Financial Officer

Jeff Caravella

Acting Chief Medical Officer

Martin Bexon

Chief Medical Officer

Humphrey Gardner

Chief Business Officer

Brent Meadows